MADRID, June 10 / PRNewswire / – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced RocheDiabetes InsulinStart at the 13th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD) in Madrid, Spain. Roche Diabetes InsulinStart is designed to support people with type 2 diabetes who start long-term insulin therapy injected once a day. The message-based service can provide real relief to people with type 2 diabetes and help doctors personalize diabetes treatment. In December 2019, Roche received the CE marking for the Roche Diabetes Insulin Start Service. The certification paves the way for pilot projects and studies that generate evidence.
– RocheDiabetes InsulinStart is a service for people with type 2 diabetes that is designed to facilitate the transition from oral antidiabetic drugs to supplementary, long-acting insulin therapy.
– Using proven algorithms, the message-based service provides support in the critical phase of finding the optimal dose for long-acting insulin injected once a day.
– The RocheDiabetes InsulinStart Service, which was initially integrated into the Accu-Chek Smart Pix software and later into the RocheDiabetes Care Platform, is now part of Roche’s open ecosystem and is intended to contribute to more effective and personalized diabetes management.
When oral antidiabetic drugs alone can no longer control blood sugar, adding a fixed amount of complementary, long-acting insulin is a preferred therapy option. The start of this so-called basal insulin-assisted oral therapy (BOT) presents both patients and doctors with challenges. The frustration of not getting a grip on type 2 diabetes is often accompanied by the fear of injecting too much or too little insulin.
Many people with diabetes feel overwhelmed to adhere to the titration scheme to optimize treatment. Studies show that less than 40% of people with diabetes reach their glycemic target at the end of their insulin adjustment period1, and more than 80% of patients tend to stop insulin therapy the first year after starting2. These results indicate that there is a clear need to optimize titration in clinical practice.
RocheDiabetes InsulinStart promises support in this critical phase. Doctors register their patients with the RocheDiabetes InsulinStart service. These are then accompanied by the process of gradually increasing the long-acting insulin to achieve their optimal individual dosage. You will receive a text message in the morning of a fasting blood sugar measurement and in the evening a recommendation for the insulin dose.
“RocheDiabetes InsulinStart fulfills the needs of people who need to inject long-term effective insulin once a day with a simple service that enables them to successfully start their unfamiliar therapy. It enables them to independently and safely manage their therapy in everyday life” , says Matthias Koehler, Senior Solutions Development Manager. The service can also be used by people who have already received insulin therapy but who need adjustment to better control their type 2 diabetes.
The Roche Diabetes Insulin Start service is offered as an add-on within the Accu-Chek Smart Pix software; a software that offers decision and therapy support in the doctor’s office. Doctors can adjust the therapy transition to the patient’s needs and view the patient’s blood sugar and injected insulin levels at any time during this phase. This helps to avoid additional visits to the practice and at the same time offers clear, actionable support to enable a simple and effective start to long-lasting insulin therapy. After four to 12 weeks, the participants are usually within their personal target area and can continue with the individually determined, long-acting insulin dose.
According to the International Diabetes Federation3, there are currently almost half a billion (463 million) adults with diabetes worldwide; by 2045 this number will increase to 700 million. The most common form is type 2 diabetes, which accounts for around 90% of all diabetes cases. Controlling blood sugar levels is critical to preventing long-term micro- and macrovascular complications.5 Basal insulin is one of the suggested treatments for patients with type 2 diabetes whose diabetes cannot be controlled with oral antidiabetic drugs alone.6 As with many chronic Diseases, the achievement of optimal therapeutic results depends on both the treatment capacity and the adherence to therapy. In these aspects in particular, the Roche Diabetes Insulin Start service offers support to enable a better response to the therapy needs of people with diabetes.
swell  Riddle et al: The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26 (11): 3080-6. Target is defined as FPG <= 100 mg / dl (5.6 mmol / l) after 24 weeks.  Ascher-Suvanum et al: Early discontinuation and restart of insulin in the treatment of type 2 diabetes mellitus. Diabetes Ther 5: 225-42, 2014. Estimated probability of discontinuation was defined as a gap in insulin injections of at least 30 days.
 IDF Diabetes Atlas 9th ed., International Diabetes Federation, 2019  UK Prospective Diabetes Study Group: “Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33).” Lancet 352 (9131): 837-853 (1998).  American Diabetes, A .: “9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2020.” Diabetes Care 43 (Suppl 1): S98-S110 (2020).
About Roche Diabetes Care
Roche Diabetes Care has been a pioneer in diabetes technologies and services for over 40 years. As the world leader in integrated diabetes management, we employ 5,000 people in over 100 markets worldwide who work every day to help people with diabetes and people at risk of diabetes so that their goals last longer and are a real relief to them experience daily therapy routine.
Roche Diabetes Care works with people with diabetes, caregivers, healthcare providers and payers. Roche Diabetes Care aims to optimally counter this complex disease and to contribute to sustainable treatment structures. With the brands RocheDiabetes, Accu-Chek and mySugr and in cooperation with partners, Roche Diabetes Care creates value with integrated solutions for measuring blood sugar levels, delivering insulin and monitoring, and for contextualizing relevant data points for successful therapy. By creating and collaborating in an open ecosystem, connecting devices and digital solutions, and contextualizing relevant data points, Roche Diabetes Care enables deeper insight and a better understanding of the disease, resulting in personalized and effective therapy and better therapy results.
MySugr has been part of Roche Diabetes Care since 2017 with its worldwide leading mobile diabetes management app and its range of services.
Visit www.rochediabetes.com for more information
, www.accu-chek.com and www.mysugr.com.
Roche is a global pioneer in pharmaceuticals and diagnostics that focuses on advancing science to improve people’s quality of life. Thanks to the combined strengths of pharmaceuticals and diagnostics under one roof, Roche has become the leading company for personalized healthcare – a strategy that aims to match the right treatment to each patient in the best possible way.
Roche is the world‘s largest biotechnology company with differentiated medicines in the areas of oncology, immunology, infectious diseases, ophthalmology and central nervous system diseases. Roche is also the global market leader in in-vitro diagnostics and tissue-based cancer diagnostics and is at the forefront of diabetes management.
Roche was founded in 1896 and has since been looking for better and better ways to prevent, diagnose and treat diseases and to make a sustainable contribution to society. The company also aims to improve patient access to medical innovation through collaboration with everyone involved. More than thirty drugs developed by Roche have been added to the World Health Organization’s list of essential drugs, including life-saving antibiotics, antimalarials, and cancer drugs. Roche has been recognized by the Dow Jones Sustainability Indices (DJSI) as the most sustainable company (group leader) in the pharmaceutical, biotechnology and life sciences industry for eleven years in a row.
The Roche Group, headquartered in Basel, Switzerland, operates in over 100 countries and in 2019 employed around 98,000 people worldwide. In 2019, Roche invested CHF 11.7 billion in research and development and generated sales of CHF 61.5 billion. Genentech in the United States is a wholly owned subsidiary of the Roche Group. Roche is the majority owner of Chugai Pharmaceuticals in Japan. Further information
are available at www.roche.com.
All trademarks used or mentioned in this press release are protected by law.
Questions & contact:
– Soo-Jin Pak (email@example.com)
– Yvette Petillon (firstname.lastname@example.org)
Logo – mma.prnewswire.com/media/780504/Roche_Logo.jpg